Last 26.95 INR
Change Today +1.75 / 6.94%
Volume 82.4K
CBIO On Other Exchanges
Symbol
Exchange
Natl India
As of 7:05 AM 07/11/14 All times are local (Market data is delayed by at least 15 minutes).

celestial biolabs ltd (CBIO) Snapshot

Open
25.10
Previous Close
25.20
Day High
27.85
Day Low
24.75
52 Week High
07/1/14 - 30.05
52 Week Low
11/13/13 - 14.35
Market Cap
434.0M
Average Volume 10 Days
164.3K
EPS TTM
0.63
Shares Outstanding
16.1M
EX-Date
09/23/09
P/E TM
43.0x
Dividend
--
Dividend Yield
--
Current Stock Chart for CELESTIAL BIOLABS LTD (CBIO)

Related News

No related news articles were found.

celestial biolabs ltd (CBIO) Related Businessweek News

No Related Businessweek News Found

celestial biolabs ltd (CBIO) Details

Celestial Biolabs Limited is engaged in new drug molecular development and biotech formulation primarily in India. The company offers a range of enzyme products for use in detergent, textile, pulp and paper, poultry feed additives, grain based distillery, molasses based distillery, sugar, food processing industrial segments. Its herbal products include syrups, such as liver tonics, blood purifiers, digestive syrups, gynocel syrups, dry fruit syrups, and syrup to treat cough and allergic disorders; capsules to treat inflammatory diseases, neuro muscular and cerebrovascular disorders, sinusitis, and UTRI and fever; tranquilizer, and bronchitis and bronchial asthma tablets; and granules, oil, lehyams, creams, and powders. The company also provides nutraceuticals for bone and joint health, cancer risk reduction, cardiovascular health, cognitive and mental function, diabetes, energy and endurance, eye and gut health, immune system, maternal and infant health, respiratory health, skin health, weight management, and women's health. In addition, it develops ERP for the biopharmaceutical and healthcare industry in the verticals of pharma, chemicals, bulk drugs, biotechnology, and hospitals and medical retail chains. Further, the company delivers SAP consulting, SAP implementation, and post-SAP implementation services, including configuration set up, customization/enhancement of existing SAP functionality, post-SAP implementation support, business process analysis/gap analysis, and business process mapping; and molecular modeling, pharmaco vigilance, medical writing, and clinical data and clinical data management services. The company was formerly known as Celestial Technologies Limited and changed its name to Celestial Technologies Limited in February 2004. Celestial Biolabs Limited was incorporated in 1997 and is based in Hyderabad, India.

Founded in 1997

celestial biolabs ltd (CBIO) Top Compensated Officers

Chairman, Managing Director and Member of Aud...
Total Annual Compensation: 660.0K
Compensation as of Fiscal Year 2013.

celestial biolabs ltd (CBIO) Key Developments

Celestial Biolabs Ltd. Launches Cadalmin Gae, Marine Derived, Developed, Formulated Clinically Tested and Patented Natural Product

Celestial Biolabs Ltd. has launched Cadalmin Gae, a marine derived, developed, formulated clinically tested and patented natural product to treat arthritis (all kinds of joint pain). The product has received remarkable response from doctors as well as patients. The product is effective, safe and vegetarian. In order to reach to all the affected people suffering with arthritis, company is planning to take this product to OTC route of marketing so that majority of the people affected with joints pain can be benefitted.

Celestial Biolabs Ltd. Announces Audited Standalone Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2014

Celestial Biolabs Ltd. announced audited standalone earnings results for the fourth quarter and full year ended March 31, 2014. For the quarter, the company announced net sales or income from operations of INR 82.041 million compared to INR 36.056 million a year ago. Profit from operations before other income, finance costs and exceptional items were INR 13.758 million compared to INR 1.836 million a year ago. Loss from ordinary activities before tax was INR 3.268 million compared to INR 0.316 million a year ago. Net loss was INR 1.232 million or INR 0.19 per basic and diluted share for before and after extraordinary items compared to net profit of INR 0.231 million or INR 0.02 per basic and diluted share for before and after extraordinary items a year ago. For the full year, the company announced net sales or income from operations of INR 235.034 million compared to INR 211.554 million a year ago. Profit from operations before other income, finance costs and exceptional items were INR 27.696 million compared to INR 9.574 million a year ago. Profit from ordinary activities before tax was INR 5.525 million compared to INR 3.115 million a year ago. Net profit was INR 8.440 million or INR 0.49 per basic and diluted share for before and after extraordinary items compared to INR 7.085 million or INR 0.49 per basic and diluted share for before and after extraordinary items a year ago.

Celestial Biolabs Ltd., Board Meeting, May 30, 2014

Celestial Biolabs Ltd., Board Meeting, May 30, 2014. Agenda: To consider and approve audited standalone earnings results for the fourth quarter and full year ended March 31, 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CBIO:IN 26.95 INR +1.75

CBIO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CBIO.
View Industry Companies
 

Industry Analysis

CBIO

Industry Average

Valuation CBIO Industry Range
Price/Earnings 96.8x
Price/Sales 0.7x
Price/Book 0.2x
Price/Cash Flow 7.5x
TEV/Sales 1.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CELESTIAL BIOLABS LTD, please visit www.celestiallabs.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.